Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19128051 | 1.00 | HPGD (0.42) | HPGDADORA2AADORA2BNT5EHINT1 | |
| SCHEMBL23384008 | 0.94 | HPGD (0.38) | HPGDADORA2AADORA2BNT5EHINT1 | |
| SCHEMBL19128056 | 0.86 | NT5E (0.38) | HPGDNT5EHINT1IMPDH2 | |
| SCHEMBL19128883 | 0.84 | TYMP (0.49) | HPGDNT5EHINT1IMPDH2 | |
| SCHEMBL19035636 | 0.80 | HINT1 (0.48) | HPGDADORA2AADORA2BHINT1ADORA3 | |
| SCHEMBL16822303 | 0.80 | HINT1 (0.48) | HPGDADORA2AADORA2BHINT1ADORA3 | |
| SCHEMBL16840864 | 0.80 | HINT1 (0.48) | HPGDADORA2AADORA2BHINT1ADORA3 | |
| SCHEMBL16822302 | 0.80 | HINT1 (0.48) | HPGDADORA2AADORA2BHINT1ADORA3 | |
| SCHEMBL16840859 | 0.79 | HPGD (0.64) | HPGDADORA2AHINT1ADORA3ADORA1 | |
| SCHEMBL7259261 | 0.79 | HPGD (0.64) | HPGDADORA2AHINT1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | HPGD 1258/4885ADORA2A 264/4885ADORA2B 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.